Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results

Kodiak Sciences Inc. (KOD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results PALO ALTO, Calif., November 12, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended Septe

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$KOD
Bullish
high confidence
Mentioned
$KOD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$KODBullishHigh
01

Why it matters

The disclosed data represent the first public release of statistically significant Phase 3 results, likely prompting a short‑term rally.

02

Market read

First‑report clinical data and cash raise provide fresh material for traders; expected immediate price impact.

03

What to watch

Reliance on a single product line (Zenkuda) and execution risk of upcoming BLA filings.

Relevance 7/10Novelty 9/10Timing: today
AlphAI · Earnings readKOD · Q3 2026 · ended 2026-09-30

Kodiak reports Q3 2026 net loss of $66.2 million, $88.7 million cash at quarter end, and $69 million of subsequent ATM proceeds, alongside positive Zenkuda and tabirafusp-ted Phase 3 DAYBREAK readouts

↓Weak quarter

The quarter shows a larger net loss than the prior year quarter in dollar terms ($66.2 million versus $61.5 million), a cash balance of $88.7 million against $209.9 million at December 31, 2025, and stockholders' equity of $12.6 million. The filing states the company's ability to fund operations into 2027 and includes going concern risk language. Clinical progress is reported, but the financial position is weak.

EPS · GAAP
$(1.05)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net loss, Q3 2026 (three months ended September 30, 2026)GAAP$66.2M––
Net loss per share, basic and diluted, Q3 2026GAAP$(1.05)––
Research and development expenses, Q3 2026GAAP$58.3M––
General and administrative expenses, Q3 2026GAAP$8.8M––
Total operating expenses, Q3 2026 (three months)GAAP$67.10M––
Loss from operations, Q3 2026 (three months)GAAP−$67.10M––
Interest income, Q3 2026 (three months)GAAP$899K––
Other income (expense), net, Q3 2026 (three months)GAAP−$24K––
Non-cash stock-based compensation expense, Q3 2026GAAP$12.8M––
Net loss, nine months ended September 30, 2026GAAP−$190.0M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$(3.04)––
Research and development expenses, nine months ended September 30, 2026GAAP$162.9M––
General and administrative expenses, nine months ended September 30, 2026GAAP$30.78M––
Total operating expenses, nine months ended September 30, 2026GAAP$193.7M––
Loss from operations, nine months ended September 30, 2026GAAP−$193.7M––
Interest income, nine months ended September 30, 2026GAAP$3.79M––
Other income (expense), net, nine months ended September 30, 2026GAAP−$106K––

Capital returns

  • Subsequent to September 30, 2026, Kodiak raised aggregate net proceeds of $69 million from sales of common stock under its at-the-market (ATM) equity offering facility.
  • No share repurchases or dividends are reported in the filing.

What drove it

  • The company states that the increase in R&D expenses in Q3 2026 was primarily driven by increased clinical activities related to the active PEAK/PINNACLE and ALTO studies and increased manufacturing activities to support its Phase 3 programs.
  • The company states that the remaining decrease in G&A expenses was primarily driven by a non-cash non-recurring gain recognized upon termination of one of its Palo Alto, California building leases, in exchange for which it received an option to lease a separate building on the same campus with certain lease incentives.
  • Zenkuda met the primary endpoint in Phase 3 DAYBREAK (p-value of 0.0007), with 54% of patients on 6-month dosing, and the company describes safety as consistent with the aflibercept profile.
  • Tabirafusp-ted met the vision primary endpoint (p-value of 0.0036) and anatomical key secondary endpoint (p-value of <0.0001) in Phase 3 DAYBREAK in wet AMD.
  • Enrollment of the first 300-patient KSI-101 pivotal cohort in PEAK has completed, with topline results on track for December 2026.

Concerns

  • Net loss for the nine months ended September 30, 2026 was $(190,024) thousand, compared with $(173,231) thousand for the same period of 2025, and R&D expenses for the nine months rose to $162,934 thousand from $136,880 thousand.
  • Cash and cash equivalents fell to $88.7 million at September 30, 2026 from $209.9 million at December 31, 2025, and the company relied on $69 million of net ATM proceeds raised after quarter end.
  • Stockholders' equity was $12,572 thousand at September 30, 2026, down from $157,383 thousand at December 31, 2025.
  • Working capital declined to $38,146 thousand from $169,283 thousand at December 31, 2025.
  • The company's forward-looking statements list the risk that its financial condition raises substantial doubt about its ability to continue as a going concern, and that sufficient capital may not be available.
  • The G&A decline in the quarter is attributed by the company to a non-recurring gain on a lease termination, which is not part of ongoing operating activity.

What to watch

  • Topline results from the PEAK Pivotal Analysis 1 for KSI-101, expected in December 2026, with the company stating the first KSI-101 results will be announced in December.
  • Submission of the multi-indication Zenkuda BLA (wet AMD, DR and RVO) by year end 2026, as planned by the company.
  • Enrollment completion in the second KSI-101 pivotal cohort of 600 subjects across PEAK and PINNACLE in Q4 2026, with topline data anticipated in Q2 2027.
  • Planned KSI-101 BLA submission in Q2 2027 if the results are successful, as stated by the company.
  • Progress of enrollment in the ALTO Phase 3 DME study for tabirafusp-ted, which the filing describes as actively enrolling.
  • Further ATM equity sales and the company's cash position relative to its statement that current cash supports operations into 2027.

Balance sheet and cash flow

  • Cash and cash equivalents: $88.7 million at September 30, 2026, versus $209.9 million at December 31, 2025 (balance sheet table: $88,678 thousand versus $209,862 thousand).
  • Working capital: $38,146 thousand at September 30, 2026, versus $169,283 thousand at December 31, 2025.
  • Total assets: $209,413 thousand at September 30, 2026, versus $351,533 thousand at December 31, 2025.
  • Accumulated deficit: $(1,748,729) thousand at September 30, 2026, versus $(1,558,705) thousand at December 31, 2025.
  • Total stockholders' equity: $12,572 thousand at September 30, 2026, versus $157,383 thousand at December 31, 2025.
  • The company expects that its current cash and cash equivalents will support its current and planned operations into 2027.
  • The forward-looking statements section lists as a risk that the company's financial condition raises substantial doubt about its ability to continue as a going concern.

Analysis

Kodiak's Q3 2026 release combines clinical progress with a weak financial position. Management reports that Zenkuda met the primary endpoint in the Phase 3 DAYBREAK study with a p-value of 0.0007, that 54% of patients were on 6-month dosing, and that the company plans a multi-indication BLA by year end covering five Phase 3 studies. Tabirafusp-ted also met its vision primary endpoint and anatomical key secondary endpoint in DAYBREAK, and the ALTO Phase 3 study in diabetic macular edema is enrolling. The filing reports no revenue, so the quarter is judged on spending, cash and funding.

Spending rose on the development side. R&D expenses were $58.3 million in Q3 2026 against $50.5 million in Q3 2025, and $162.9 million for the nine months against $136.9 million a year earlier. The company attributes the quarterly increase to clinical activity in the PEAK/PINNACLE and ALTO studies and to manufacturing for its Phase 3 programs. G&A fell to $8.8 million from $11.9 million, and the company says the decline was driven primarily by a non-cash, non-recurring gain on termination of a Palo Alto building lease. Total operating expenses were $67,098 thousand against $62,352 thousand a year earlier, and the net loss was $66.2 million, or $1.05 per share, against $61.5 million, or $1.16 per share. The per-share loss is smaller than a year ago only because the weighted-average share count rose, from 52,859,308 to 62,960,644 in the three months.

The balance sheet shows the funding pressure. Cash and cash equivalents were $88.7 million at September 30, 2026, against $209.9 million at December 31, 2025, and total assets fell to $209,413 thousand from $351,533 thousand. Stockholders' equity was $12,572 thousand against $157,383 thousand at year end, and working capital was $38,146 thousand against $169,283 thousand. After quarter end the company raised $69 million in net proceeds through its ATM facility. Management states that current cash supports operations into 2027. The forward-looking statements also name going concern doubt as a risk, which reads as a direct statement about the financing position.

The near-term catalysts are concrete and dated in the filing. The first PEAK Pivotal Analysis 1 readout for KSI-101 is expected in December 2026, the Zenkuda BLA is planned by year end, and the second KSI-101 pivotal cohort is expected to enroll in Q4 2026 with topline data in Q2 2027. The filing gives no financial guidance, no revenue outlook and no prior-period outlook to compare against, so no guidance verdicts are made here. The reader should weigh the clinical timeline against the cash balance, the equity position and the reliance on equity issuance shown in this release.

Management, verbatim

We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company,

Victor Perlroth, M.D., Chief Executive Officer

We are also on track to submit the multi-indication BLA for Zenkuda by year end, supported by five successful Phase 3 studies,

Victor Perlroth, M.D., Chief Executive Officer

Not in the filing

stated, not guessed
  • No financial guidance (revenue, operating expenses, cash burn) is printed in the filing, so guidance is null.
  • No prior outlook was provided, so vs_prior_guidance is empty.
  • Year-over-year and sequential percentage changes are not printed for any line, so yoy_change and qoq_change are null.
  • Q2 2026 (prior quarter) results are not in the filing, so prior_quarter is null for all metrics.
  • Revenue, cost of sales and gross margin are not reported in the filing, consistent with a precommercial company.
  • No segment breakdown is provided in the filing.
  • Cash flow statement (operating, investing and financing cash flow) is not included in the filing.
  • Debt balances and total liabilities are not reported.
  • Consensus estimates, analyst expectations and share price reaction are not in the documents.
  • Gross and net proceeds per share from the ATM program and the number of shares sold are not reported.
  • Net loss and expense comparisons for Q3 2026 are printed in the text and table in different units; the text figures are used for the headline lines and the table figures for the statement lines.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Kodiak Sciences filed a Form 8‑K reporting Q3 2026 results and key Phase 3 trial outcomes for its retinal‑disease assets.

Company-level read

Ticker impact

$KODBullishHigh confidence
Context

Kodiak Sciences disclosed positive Phase 3 results for Zenkuda and Tabirafusp‑ted and announced upcoming readouts, alongside Q3 2026 financials.

Expected impact

upward pressure as investors price in successful Phase 3 outcomes and future BLA filing potential

Evidence & confidence

First‑report 8‑K with statistically significant Phase 3 endpoints (p‑values 0.0007 and 0.0036) and a $69 M ATM raise, both material catalysts for a biotech.

Market effects

Boosts confidence in retinal‑disease biotech pipeline, may lift peer valuations.

Positive for US biotech sector.

Limited to investors tracking ophthalmology therapeutics worldwide.

Counterpoint

High cash burn and net loss could pressure the stock if trial readouts miss expectations.

Key entities

  • Kodiak Sciences Inc.

    Nasdaq‑listed biotech developing retinal therapies.

Every KOD earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$KODMedAI 8/10

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences (KOD) reported a Q3 2026 loss of $1.05 per share, wider than expected. R&D expenses rose 15.5% YoY, while cash reserves decreased to $88.7M. The company raised $69M via stock sales. Positive phase III data for Zenkuda and abirafusp-ted were announced, with BLA submissions planned. KOD shares surged 287.1% YTD.

$KODHighAI 8/10

KOD Stock Explodes As Zenkuda Trial Data Rewire Wall Street

Kodiak Sciences Inc (KOD) stock rose 7.91% on October 19, 2026, following positive trial data for its eye drug Zenkuda. The company reported successful Phase 3 DAYBREAK trial results, with analysts raising price targets. KOD has no revenue but has cash and working capital for operations. The stock has seen significant volatility, with some analysts remaining neutral due to valuation concerns.

$KODHighAI 9/10

KOD Stock Soars As Zenkuda Trial Fuel Sparks Massive Re‑Rating

Kodiak Sciences Inc (KOD) surged 8.56% after positive Phase 3 trial results for Zenkuda and tabirafusp-ted, showing non-inferior vision gains to aflibercept. Analysts raised price targets, with LifeSci Capital at $145 and Jefferies at $112. KOD has $132.1M in cash, negative operating cash flow, and a current ratio of 2.5.

$KODMed

KOD Stock Rockets As DAYBREAK Trial Rewrites Biotech Expectations

Kodiak Sciences Inc (KOD) rose 8.56% on October 15, 2026, following positive Phase 3 DAYBREAK trial results for its treatments Zenkuda and tabirafusp-ted. The trial met primary endpoints, showing vision gains and favorable safety. Analysts raised price targets, with LifeSci Capital setting it at $145. KOD's stock surged over 100% on September 28, 2026, after the trial news. The company remains pre-revenue but has a strong cash position.

$KODHighAI 8/10

Kodiak Sciences Tumbles Despite Strong Phase 3 Trial

Kodiak Sciences (KOD) shares fell 7.84% despite positive Phase 3 trial results, as investors took profits and raised concerns about competition and commercial infrastructure. The company's long-term prospects remain uncertain due to cash burn and funding needs, despite strong clinical data. KOD has a market cap of $6.24B and is up 255.01% YTD.